Department of Clinical Laboratory Immunology, Churchill Hospital, Oxford, UK.
Hum Immunol. 2013 Dec;74(12):1531-5. doi: 10.1016/j.humimm.2013.08.266. Epub 2013 Aug 28.
Autoimmune lymphoproliferative syndrome (ALPS) is a disorder of dysregulated lymphocyte homeostasis. Biomarkers including elevated CD3+TCRαβ+CD4-CD8- double negative T cells (TCRαβ+ DNT), IL-10, sCD95L and vitamin B12 can be used to differentiate between ALPS and common variable immunodeficiency (CVID) patients with an overlapping clinical phenotype. We investigated the utility of ALPS biomarkers in 13 CVID patients with lymphoproliferation and/or autoimmune cytopaenia with comparison to 33 healthy controls. Vitamin B12 (P < 0.01) and IL-10 (P < 0.0001), but not sCD95L or TCRαβ+ DNT, were increased in CVID compared to controls. The 95th percentile for TCRαβ+ DNT in healthy controls was used to define a normal range up to 2.3% of total lymphocytes or 3.4% of T cells. These frequencies lie markedly beyond the cut offs used in current ALPS diagnostic criteria (≥ 1.5% of total lymphocytes or 2.5% of CD3+ lymphocytes), suggesting these limits may have poor specificity for ALPS.
自身免疫性淋巴组织增生综合征 (ALPS) 是一种淋巴细胞稳态失调的疾病。包括升高的 CD3+TCRαβ+CD4-CD8- 双阴性 T 细胞 (TCRαβ+ DNT)、IL-10、sCD95L 和维生素 B12 在内的生物标志物可用于区分 ALPS 和具有重叠临床表型的常见可变免疫缺陷 (CVID) 患者。我们研究了 13 例伴有淋巴增生和/或自身免疫性血细胞减少的 CVID 患者的 ALPS 生物标志物的实用性,并与 33 名健康对照进行了比较。与对照组相比,CVID 患者的维生素 B12 (P < 0.01) 和 IL-10 (P < 0.0001) 升高,但 sCD95L 或 TCRαβ+ DNT 升高。健康对照组 TCRαβ+ DNT 的第 95 百分位数用于定义正常范围,占总淋巴细胞的 2.3%或 T 细胞的 3.4%。这些频率明显超过当前 ALPS 诊断标准中使用的截止值 (≥总淋巴细胞的 1.5%或 CD3+淋巴细胞的 2.5%),表明这些限制可能对 ALPS 的特异性较差。